Benedetta Conte1, Alessandra Fabi2, Francesca Poggio3, Eva Blondeaux3, Chiara Dellepiane3, Alessia D'Alonzo3, Giuseppe Buono4, Grazia Arpino4, Valentina Magri5, Giuseppe Naso5, Daniele Presti6, Silvia Mura7, Andrea Fontana8, Francesco Cognetti9, Chiara Molinelli3, Simona Pastorino3, Claudia Bighin3, Loredana Miglietta3, Francesco Boccardo10, Matteo Lambertini10, Lucia Del Mastro11. 1. Department of Medical Oncology, Ospedale Policlinico San Martino, University of Genova, Genoa, Italy. Electronic address: bntconte@gmail.com. 2. Division of Medical Oncology, 'Regina Elena' National Cancer Institute, Rome, Italy. 3. Department of Medical Oncology, Ospedale Policlinico San Martino, University of Genova, Genoa, Italy. 4. Department of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II, Naples, Italy. 5. Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy. 6. Unit of Medical Oncology, IRCCS ICS Maugeri, University of Pavia, Pavia, Italy. 7. Medical Oncology Unit, University-Hospital of Sassari (AOU), Sassari, Italy. 8. Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy. 9. Department of Clinical and Molecolar Medicine, La Sapienza University, Rome, Italy. 10. Department of Internal Medicine and Medical Specialties, University of Genova, Genoa, Italy; Academic Unit of Medical Oncology, Ospedale Policlinico San Martino, Genoa, Italy. 11. Department of Medical Oncology, Ospedale Policlinico San Martino, University of Genova, Genoa, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genoa, Italy.
Abstract
BACKGROUND: T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy. PATIENTS AND METHODS: Eligible patients were identified within the Gruppo Italiano Mammella (GIM) 14/BIOMETA study, a retrospective/prospective multicenter study on treatment patterns and outcomes of patients with metastatic breast cancer (ClinicalTrials.gov Identifier: NCT02284581). We searched for patients who received second-line T-DM1 after taxane plus trastuzumab and pertuzumab between November 15, 2013 and May 31, 2018. We calculated median PFS, median time to treatment failure (TTF), prolonged duration of therapy (PDT), objective response rate (ORR), and 1-year OS. RESULTS: Of 445 patients with HER2+ metastatic breast cancer, 77 were eligible for the analysis. At a median follow-up of 7 months, median PFS was 6.3 months (95% confidence intervals [CI], 4.8-7.7 months), and median TTF was 6.2 months (95% CI, 4-8.6 months). More than one-third of patients (37.6%; n = 29) experienced PDT with an ORR of 27.1%. At data cutoff, the median OS was not reached, and the 1-year OS was 82%. CONCLUSIONS: Our results show meaningful activity of T-DM1 after front-line pertuzumab plus trastuzumab and a taxane, with about 27% of patients having an objective response and 40% of patients achieving durable disease control.
BACKGROUND: T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic humanepidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy. PATIENTS AND METHODS: Eligible patients were identified within the Gruppo Italiano Mammella (GIM) 14/BIOMETA study, a retrospective/prospective multicenter study on treatment patterns and outcomes of patients with metastatic breast cancer (ClinicalTrials.gov Identifier: NCT02284581). We searched for patients who received second-line T-DM1 after taxane plus trastuzumab and pertuzumab between November 15, 2013 and May 31, 2018. We calculated median PFS, median time to treatment failure (TTF), prolonged duration of therapy (PDT), objective response rate (ORR), and 1-year OS. RESULTS: Of 445 patients with HER2+ metastatic breast cancer, 77 were eligible for the analysis. At a median follow-up of 7 months, median PFS was 6.3 months (95% confidence intervals [CI], 4.8-7.7 months), and median TTF was 6.2 months (95% CI, 4-8.6 months). More than one-third of patients (37.6%; n = 29) experienced PDT with an ORR of 27.1%. At data cutoff, the median OS was not reached, and the 1-year OS was 82%. CONCLUSIONS: Our results show meaningful activity of T-DM1 after front-line pertuzumab plus trastuzumab and a taxane, with about 27% of patients having an objective response and 40% of patients achieving durable disease control.
Authors: Luai S Al Rabadi; Madeline M Cook; Andy J Kaempf; Megan M Saraceni; Michael A Savin; Zahi I Mitri Journal: BMC Cancer Date: 2021-10-27 Impact factor: 4.430
Authors: Rupert Bartsch; Simon Peter Gampenrieder; Gabriel Rinnerthaler; Edgar Petru; Daniel Egle; Andreas Petzer; Marija Balic; Ursula Pluschnig; Thamer Sliwa; Christian Singer Journal: Wien Klin Wochenschr Date: 2022-01-28 Impact factor: 1.704
Authors: Salvatore Del Prete; Liliana Montella; Grazia Arpino; Giuseppe Buono; Carlo Buonerba; Pasquale Dolce; Olga Fiorentino; Maria Aliberti; Antonio Febbraro; Clementina Savastano; Giuseppe Colantuoni; Ferdinando Riccardi; Angela Ruggiero; Sabino De Placido; Michele Orditura Journal: Oncotarget Date: 2020-06-02